Intellia Therapeutics
Update in progressNTLA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Intellia Therapeutics is a clinical-stage gene editing company developing potentially curative genome editing medicines. Its in vivo programs include NTLA-2001, a Phase 1 trial for transthyretin amyloidosis, and NTLA-2002, a Phase 1/2 study for hereditary angioedema. It has collaborations with AvenCell Therapeutics for allogeneic universal CAR-T, Kyverna for allogeneic CD19 CAR-T in autoimmune diseases, ONK for engineered NK therapies, and ReCode for cystic fibrosis. Founded 2014, based in Cambridge, MA.
Company score
- Sentiment
- -0.20
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.27
- Governance
- -0.19
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.16
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. John M. Leonard M.D.
- Founded2014
- Employees377
- Websitewww.intelliatx.com
Identifiers
- ISINUS45826J1051
- FIGIBBG007KC7PB0
- LEI5493002T5BCPE5DZC723
- CUSIP45826J105
- CIK0001652130